Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07307872Completed

A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease

Role: lead

NCT07294586Completed

Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease

Role: lead

NCT02973971Completed

ADDIA Chronobiological Study

Role: lead

NCT03030586Completed

ADDIA Proof-of-Performance Clinical Study

Role: lead

All 4 trials loaded